16:23 , Apr 25, 2017 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: SNPs SNPs on 17 genomic loci could help predict the risk of atrial fibrillation. Genome-wide, exome-wide and rare variant association studies in 40,277 atrial fibrillation patients and 247,228 healthy volunteers identified independent associations between...
07:00 , Aug 13, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: N-acylsphingosine amidohydrolase 1 (ASAH1)

Hepatic disease INDICATION: Hepatic Mouse studies suggest activating ASAH1 could help treat hepatic steatosis. In mouse models of diet-induced obesity, liver-specific overexpression of ASAH1 increased glucose tolerance and insulin sensitivity and decreased markers of hepatic...
08:00 , Nov 24, 2014 |  BioCentury  |  Emerging Company Profile

Breaking down ceramide

Plexcera Therapeutics LLC is developing a recombinant human acid ceramidase as a disease-modifying therapy to treat Farber disease and a subset of spinal muscular atrophy, two ultra-rare diseases for which there are no approved drugs....
07:00 , Sep 16, 2013 |  BC Week In Review  |  Company News

Plexcera Therapeutics, Icahn School of Medicine deal

The medical school granted Plexcera exclusive, worldwide rights to develop and commercialize recombinant human acid ceramidase (rhAC) . Plexcera will evaluate rhAC to treat diseases caused by genetic or disease-induced deficiencies in N-acylsphingosine amidohydrolase 1...
23:21 , Sep 13, 2013 |  BC Extra  |  Company News

Plexcera licenses recombinant ceramidase from Mount Sinai

The Icahn School of Medicine at Mount Sinai Hospital (New York, N.Y.) granted Plexcera Therapeutics LLC (Vero Beach, Fla.) exclusive, worldwide rights to develop and commercialize recombinant human acid ceramidase (rhAC) . Plexcera will evaluate...